Skip to Main Content

Paper Details

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Clin Cancer Res
126
2021
Author NameAffiliation
Annette M MolinaroUniversity of California San Francisco
John F de GrootM.D. Anderson Cancer Center
Thomas J KaleyMemorial Sloan Kettering Cancer Center
Howard ColmanHuntsman Cancer Institute, University of Utah
Howard ColmanHuntsman Cancer Institute, University of Utah
Rakesh K JainMassachusetts General Hospital
Patrick Y WenDana-Farber Cancer Institute
  • 1 - 7

Datasets

Release 1.2